# OnCo record paper-groarke-ponsegromab-cancer-cachexia-nejm-2024 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-groarke-ponsegromab-cancer-cachexia-nejm-2024/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-groarke-ponsegromab-cancer-cachexia-nejm-2024" ;
  schema:name "Ponsegromab for the Treatment of Cancer Cachexia"@en ;
  schema:description "The 2024 phase 2 trial in which an antibody blocking the hormone GDF-15 helped patients with cancer-related wasting, a third of them with pancreatic cancer, gain about two to three kilograms in twelve weeks and become more active."@en ;
  schema:url <https://onco.cc/key-papers/paper-groarke-ponsegromab-cancer-cachexia-nejm-2024/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2409515>, <https://pubmed.ncbi.nlm.nih.gov/39282907/>, <https://clinicaltrials.gov/study/NCT05546476> ;
  onco:tag "pancreatic-evidence" ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2409515> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Groarke JD, Crawford J, Collins SM, et al." ;
  onco:related <https://onco.cc/key-papers/paper-fearon-lancet-oncol/>, <https://onco.cc/roadmaps/survivorship-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/colorectal/> ;
  onco:sections <https://onco.cc/fronts/supportive-care/> ;
  onco:drugs <https://onco.cc/drugs/ponsegromab/> ;
  onco:companies <https://onco.cc/companies/pfizer/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-cachexia-supportive/> ;
  onco:journals <https://onco.cc/journals/nejm/> .